How Much Does Actos (Pioglitazone) Cost in Kentucky in 2026?

Kentucky Retail Pricing: Brand Actos vs. Generic Pioglitazone

The price gap between brand-name Actos and its generic equivalent is wide enough that almost no Kentucky prescriber writes for the brand anymore. Takeda's branded Actos carries a list price near $60 per month for 30 tablets. Generic pioglitazone, manufactured by companies including Mylan, Teva, and Sun Pharma, averages roughly $15 per month at Kentucky retail chains such as Kroger, Walgreens, and CVS.

That $15 figure reflects the average 2026 cash-pay price across Kentucky zip codes without insurance or coupon discounts applied. Prices shift by a few dollars depending on the specific pharmacy and tablet strength. The 15 mg and 30 mg tablets typically cost the same; the 45 mg tablet can run $1 to $3 higher per fill. Walmart and Costco pharmacies in Lexington, Louisville, and Bowling Green frequently price 30-day supplies of generic pioglitazone below $10 on their discount formularies.

Pioglitazone belongs to the thiazolidinedione (TZD) class. The FDA-approved labeling indicates it for type 2 diabetes as monotherapy or in combination with metformin, sulfonylureas, or insulin [1]. Its mechanism improves insulin sensitivity at the adipose tissue, skeletal muscle, and liver by activating PPAR-gamma receptors. A single daily dose, no titration requirement after the initial 15 mg or 30 mg starting dose, and generic availability make it straightforward for both patients and pharmacies.

Kentucky Medicaid Coverage for Pioglitazone

Kentucky Medicaid, administered through managed care organizations (MCOs) including Aetna Better Health, Humana CareSource, Anthem, Molina, and WellCare, does not list Actos or generic pioglitazone on its preferred drug list as of early 2026. This means that Medicaid enrollees face a prior authorization requirement before the drug is covered.

The prior authorization pathway typically requires documentation that the patient has tried and failed metformin (or has a contraindication), and that a TZD is clinically appropriate. Kentucky MCOs generally approve pioglitazone prior authorizations within 24 to 72 hours when the prescriber submits lab evidence of inadequate glycemic control (HbA1c above 7.0%) and a statement of metformin intolerance or contraindication.

The American Diabetes Association Standards of Care position TZDs as a second- or third-line option after metformin and SGLT2 inhibitors or GLP-1 receptor agonists, particularly when insulin sensitization or MASH is a treatment goal [2]. Clinicians seeking Medicaid approval for pioglitazone in Kentucky may reference the ADA algorithm as supporting evidence in the prior authorization form.

For patients who cannot secure prior authorization, the out-of-pocket cost of $15 per month at retail or below $10 with a coupon makes pioglitazone affordable even without Medicaid reimbursement.

Insurance Coverage Across Kentucky Commercial Plans

Most Kentucky commercial insurers place generic pioglitazone on Tier 1 (preferred generic) or Tier 2 (non-preferred generic). This translates to a typical copay of $0 to $15 depending on the plan design.

Anthem Blue Cross Blue Shield Kentucky, the state's largest commercial insurer, lists pioglitazone on Tier 1 for most employer-sponsored and Affordable Care Act marketplace plans. Humana, headquartered in Louisville, also places it on Tier 1 across its commercial PPO and HMO products. CareSource Kentucky marketplace plans carry pioglitazone at Tier 2 with a $10 copay for most 2026 plan designs.

Brand Actos, by contrast, sits on Tier 3 (preferred brand) or is excluded entirely on many formularies. Because the generic and brand contain identical active pharmaceutical ingredient, dose, and bioequivalence, there is no clinical reason to request brand Actos. Kentucky pharmacists will automatically dispense the generic unless the prescriber writes "dispense as written," which insurance may then decline to cover at the brand rate.

Patients enrolled in high-deductible health plans (HDHPs) paired with health savings accounts should note that pioglitazone qualifies as a preventive drug for diabetes under IRS Notice 2019-45. Some HDHPs cover it pre-deductible at $0 copay. Check with your specific plan administrator.

Compounded Pioglitazone in Kentucky: Legal and Available

Compounded pioglitazone is legal in Kentucky through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act, Section 503A), a pharmacy may compound pioglitazone from bulk pharmaceutical-grade powder for an individual patient with a valid prescription [3].

Kentucky does not impose additional state-level restrictions on 503A compounding beyond federal requirements. The Kentucky Board of Pharmacy requires that compounding pharmacies hold a valid state license and comply with USP <795> standards for non-sterile compounding.

Why would a patient choose compounded pioglitazone? The most common scenario involves custom dosing. The commercially available tablets come in 15 mg, 30 mg, and 45 mg strengths. A clinician might prescribe 7.5 mg daily (half of 15 mg) for an off-label MASH protocol or for a patient who is particularly sensitive to fluid retention. Compounding pharmacies can prepare capsules at that exact strength, eliminating the need to split tablets.

Cost varies. Some 503A pharmacies in Kentucky advertise compounded pioglitazone at prices comparable to or slightly above the generic retail price. Others bundle it into a monthly membership model. Because commercial generics are already inexpensive, the primary driver for compounding is dose customization rather than cost savings.

The MASH/NASH Evidence: Why Kentucky Clinicians Prescribe Off-Label

Pioglitazone has the strongest randomized trial evidence of any single agent for metabolic dysfunction-associated steatohepatitis. The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Nonalcoholic Steatohepatitis), published in the New England Journal of Medicine in 2010, enrolled 247 non-diabetic adults with biopsy-confirmed NASH [4].

At 96 weeks, pioglitazone 30 mg daily achieved histological resolution of NASH in 47% of patients versus 21% on placebo (P<0.001) [4]. The drug also improved steatosis, lobular inflammation, and hepatocellular ballooning scores. Vitamin E improved NASH resolution compared with placebo as well, but pioglitazone was the only agent that also significantly reduced fibrosis progression.

A 2016 meta-analysis of eight randomized trials involving 516 patients with NASH confirmed that pioglitazone improved advanced fibrosis (odds ratio 1.66 to 95% CI 1.02 to 2.73) and NASH resolution (OR 3.40 to 95% CI 2.05 to 5.64) [5]. The AASLD practice guidance for NAFLD recommends pioglitazone as a pharmacological option for patients with biopsy-confirmed NASH, with or without type 2 diabetes [6].

This evidence matters for Kentucky residents because the state has some of the highest obesity and type 2 diabetes prevalence rates in the nation. The CDC's 2023 Behavioral Risk Factor Surveillance System data reported Kentucky's adult diabetes prevalence at 14.5%, ranking it among the top five states [7]. MASH is estimated to affect 20% to 30% of adults with type 2 diabetes. Kentucky clinicians increasingly consider pioglitazone for patients with overlapping diabetes and fatty liver disease, and the drug's low cost makes it accessible even for uninsured patients.

Telehealth Prescribing in Kentucky

Kentucky permits telehealth prescribing of pioglitazone with no geographic or facility restrictions for the patient. A prescriber licensed in Kentucky can evaluate a patient via synchronous video or audio-only visit and issue a prescription for pioglitazone that the patient fills at any licensed Kentucky pharmacy.

The state's telehealth parity law (KRS 205.559 and KRS 211.336) requires commercial insurers and Medicaid MCOs to reimburse telehealth visits at the same rate as in-person visits. This means a patient in rural eastern Kentucky has the same access to a pioglitazone prescription as someone in Louisville or Lexington.

HealthRX and other telehealth platforms licensed in Kentucky can prescribe pioglitazone after a clinical evaluation that includes review of recent lab work (HbA1c, fasting glucose, liver function tests, and lipid panel). Patients receive a prescription sent electronically to their preferred pharmacy. The entire process, from intake to prescription, typically takes one to two business days.

Discount Programs and Savings Cards

Several pathways exist to reduce the already-low cost of pioglitazone in Kentucky.

Generic manufacturer coupons. Some generic manufacturers offer co-pay assistance cards that reduce the out-of-pocket cost to $0 for commercially insured patients. These cards are not valid for government insurance programs (Medicare, Medicaid, Tricare).

Pharmacy discount platforms. GoodRx, RxSaver, and SingleCare routinely list pioglitazone 30 mg #30 below $10 at Kroger, Walmart, and CVS locations across Kentucky. The discount is applied at the pharmacy counter using a coupon code. No insurance is billed.

Walmart $4/$10 list. Pioglitazone appears on the Walmart Reliance Program (formerly $4 generics list) at some Kentucky locations for $10 per 90-day supply. Pricing can vary by store.

340B pricing. Patients who receive care at federally qualified health centers (FQHCs) in Kentucky, such as Kentucky River District Health Department or Big Sandy Health Care, may access pioglitazone at 340B pricing, which is often below $5 per month.

Medicare Part D. For Kentucky Medicare beneficiaries, pioglitazone is covered under Part D. Most plans place it on Tier 1. Under the Inflation Reduction Act provisions effective 2025, the out-of-pocket maximum for Part D is capped at $2,000 annually, though pioglitazone's low cost means most patients will never approach that ceiling for this drug alone.

Side Effects and Monitoring Considerations

Pioglitazone is generally well tolerated, but Kentucky prescribers monitor for several known risks. Weight gain averaging 2 to 4 kg over the first year is common and results from fluid retention and adipocyte proliferation [1]. Peripheral edema occurs in approximately 5% of patients on monotherapy and up to 15% when combined with insulin [1].

The FDA issued a safety communication in 2011 noting a potential association between pioglitazone use exceeding 12 months and bladder cancer risk [8]. Subsequent large observational studies, including a 10-year Kaiser Permanente cohort study (N=193,099), found no statistically significant increase in bladder cancer incidence with pioglitazone use overall, though a small signal persisted in patients with cumulative exposure exceeding 28 to 000 mg [9]. The consensus among endocrinologists is that the benefit-risk ratio favors pioglitazone for most patients with type 2 diabetes or MASH, with the exception of those with active or prior bladder cancer.

The Endocrine Society recommends periodic monitoring of liver function tests, a baseline and annual DEXA scan for postmenopausal women (pioglitazone reduces bone mineral density), and assessment for signs of heart failure before initiation [10]. Pioglitazone is contraindicated in NYHA Class III or IV heart failure.

How Kentucky Compares to Neighboring States

Pioglitazone pricing in Kentucky is broadly consistent with surrounding states. Retail cash prices in Tennessee, Ohio, Indiana, West Virginia, and Virginia all cluster in the $12 to $18 range for a 30-day generic supply. The main differentiator is Medicaid coverage. Ohio Medicaid covers pioglitazone without prior authorization. Indiana Medicaid requires step therapy through metformin first. West Virginia Medicaid, like Kentucky, does not include pioglitazone on its preferred list.

For Kentucky residents near state borders, there is no financial incentive to fill prescriptions across state lines, as prices are comparable and pharmacy discount coupons work regardless of the state.